Everett, WA – July 11, 2011 – SNBL USA announced today that one of its Developmental and Reproductive Toxicology scientists, Satoru Oneda, DVM, PhD, DRDT, will be presenting a poster at the Annual JSOT Meeting to be held at PACIFIC Convention Plaza, Yokohama, Japan, July 11-13, 2011.
Dr. Oneda’s poster presentation entitled “An Immunological Response Assessment to KLH Immunization in Infant Cynomolgus Monkeys” will be available for viewing and discussion for the duration of the meeting.
SNBL USA is one of the few laboratories in the world capable of performing high quality developmental and reproductive toxicology (DART) studies in NHPs. Drawing on the wealth of experience from our qualified scientists and technical staff, SNBL USA has a well-established NHP DART program unparalleled in experience and service. Additionally, SNBL USA has an established and validated DART program extending to rodents and rabbits to offer our clients alternative species models. For additional information regarding SNBL USA’s DART program or to request a copy of the poster being presented, please contact SNBL USA at email@example.com
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging from preclinical through clinical services.